HomeNewsIndiaNearly 15% of corporate workforce may permanently work from home post COVID-19: JLL India CEO Ramesh Nair

Nearly 15% of corporate workforce may permanently work from home post COVID-19: JLL India CEO Ramesh Nair

However, he said, the de-densification of office space by corporates to ensure social distancing between employees may mitigate any adverse impact on office demand due to adoption of work-for-home (WFH) policy.

June 10, 2020 / 18:43 IST
Story continues below Advertisement

An average 13-14 percent of corporate workforce may permanently work from home - a development that may hit demand for office space slightly, JLL India country head and CEO Ramesh Nair has said.

However, he said, the de-densification of office space by corporates to ensure social distancing between employees may mitigate any adverse impact on office demand due to adoption of work-for-home (WFH) policy.

Story continues below Advertisement

Nair was speaking at a webinar organised by Workplace Trends India founder Tushar Mittal, who also heads interior design firm SKV on Tuesday.

Sanjeev Mohanty, MD, South Asia, Middle East And North Africa, Levi Strauss and Company, and Shiv Agrawal, MD, ABC Consultants were the two other speakers in the webinar titled "Will work from home be the new normal".

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show